Reviewhybrid2014

Cost-Effectiveness of Therapeutic Education to Prevent the Development and Progression of Type 2 Diabetes: Systematic Review

52 citations0/0 files storedJournal of Diabetes & Metabolism

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Health Systems, Economic Evaluations, Quality of Life Diabetes Treatment and Management Diabetes Management and Education

Abstract

Objective: To update current evidence on the cost-effectiveness (CE) of therapeutic education in prediabetes and type 2 diabetes.Research design and methods: A systematic review of economic evaluations of therapeutic education in prediabetes and type 2 diabetes, based on Randomized Controlled Trials (RCTs) and published in 2002 -2014.The quality of the clinical evidence was appraised through the Cochrane Collaboration's tool for assessing risk of bias.Economic studies were evaluated through the Consensus Health Economic Criteria List.The Incremental Cost-Effectiveness Ratios (ICERs) of patient education in prediabetes and type 2 diabetes were compared.Results: Out of 2031 identified publications, eight studies on prediabetes and nine on type 2 diabetes met the inclusion criteria.The level of the underlying clinical evidence was overall high in studies on prediabetes and varied in studies on type 2 diabetes.The mean ICER (95% CI) from the perspective of the healthcare system was €18,000 per QALY (range from dominance to €49,700) in prediabetes and €29,700 (range from €9,100 to €50,300) per QALY in type 2 diabetes.General flaws in the economic evaluations were short time horizons, limited uncertainty analysis and a lack of transparency in the modeling methods. Conclusions:The number of economic evaluations of patient education in prediabetes and type 2 diabetes has been growing in the past years.Our review compares the health economic evidence on therapeutic education for both conditions.The findings suggest that offering therapeutic education already in prediabetes stage may be a better value for money than postponing it till after the diagnosis.More robust methodologies in health economic evaluations are essential in further evidence generation.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 52 citations exist upstream.

References

2003Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies 2005Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria 2012Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 2005The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance 2002Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes 2010Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review 2012The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention 1997Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia

Cited by

2023A consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies 2017A systematic review of economic evaluations of treatments for patients with epilepsy

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.